Renal masses in the kidney graft pose an important clinical dilemma, balancing graft function against the need for cancer control.
Donor origin cancers in the renal graft can be classified as 'donor transmitted' or 'donor derived'. The landmark TracerX Renal changed our understanding of renal cell carcinoma oncogenesis, demonstrating that key mutations in childhood lead to clinically apparent tumours in later life. Identified pre-operatively, contemporary evidence suggests that masses excised prior to transplantation result in acceptable oncologic safety and graft function. Identified post-operatively management mirrors that for a mass in a solitary kidney in the non-transplant population, with focus on a nephron-sparing approach. With growing number of kidney transplants each year, ageing donors, and increasing graft survival, masses in the renal graft are likely to become a more prevalent clinical conundrum.
Current urology reports. 2020 Feb 11*** epublish ***
Hannah Warren, Jonathon Olsburgh
Department of Transplant Surgery, Guy's & St Thomas' NHS Foundation Trust, London, UK. ., Department of Transplant Surgery, Guy's & St Thomas' NHS Foundation Trust, London, UK.